Start › Niedrobnokomórkowy rak płuca › Pensylwania › Pittsburgh
Badania kliniczne dla Niedrobnokomórkowy rak płuca w mieście Pittsburgh, PA
48 badań dla Niedrobnokomórkowy rak płuca szuka uczestników w ośrodkach w mieście Pittsburgh i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RekrutacjaFaza 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekrutacjaFaza 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- i 11 więcej
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RekrutacjaFaza 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- i 8 więcej
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekrutacjaFaza 1
- Exelixis Clinical Site #32, Pittsburgh
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RekrutacjaFaza 2
- AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekrutacjaFaza 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · 11 mi dalej
- UPMC Hillman Cancer Center - Monroeville, Monroeville · 11 mi dalej
- i 1 więcej
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RekrutacjaFaza 3
- Local Institution - 0028, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RekrutacjaFaza 1
- Research Site, Pittsburgh
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RekrutacjaFaza 1
- Research Site, Pittsburgh
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RekrutacjaFaza 2
- Bryn Mawr Hospital, Bryn Mawr · 11 mi dalej
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- AHN Allegheny General Hospital, Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RekrutacjaFaza 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekrutacjaFaza 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekrutacjaFaza 1/2
- Allegheny Health Network, Pittsburgh
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekrutacjaFaza 3
- Clinical Study Site, Pittsburgh
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekrutacjaFaza 1
- UPMC, Pittsburgh
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekrutacjaFaza 2/3
- Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekrutacjaFaza 1/2
- Allegheny Singer, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekrutacjaFaza 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RekrutacjaFaza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekrutacjaFaza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RekrutacjaFaza 1
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekrutacjaFaza 1
- UPMC, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Research Site, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekrutacjaFaza 1/2
- Allegheny Health Network, Pittsburgh
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekrutacjaFaza 3
- UPMC-Shadyside Hospital, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekrutacjaFaza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RekrutacjaFaza 2
- Allegheny General Hospital, Natrona Heights · 19 mi dalej
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RekrutacjaFaza 3
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
RekrutacjaFaza 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RekrutacjaFaza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RekrutacjaFaza 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekrutacjaFaza 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- i 11 więcej
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- Research Site, Pittsburgh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekrutacjaFaza 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- i 9 więcej
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
RekrutacjaFaza 3
- Allegheny, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RekrutacjaFaza 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
RekrutacjaFaza 1
- UPMC- Hillman Cancer Center, Pittsburgh
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
RekrutacjaFaza 2
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RekrutacjaFaza 1
- Hillman Cancer Center, Pittsburgh
Impact of Circadian Rhythm on Immunotherapy
RekrutacjaFaza 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RekrutacjaFaza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
RekrutacjaFaza 2
- UPMC Hillman Cancer Center, Pittsburgh
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
Badania dla Niedrobnokomórkowy rak płuca w innych miastach
- Houston, TX145 badań
- New York City, NY121 badań
- Arlington, VA104 badań
- Nashville, TN97 badań
- Boston, MA90 badań
- Los Angeles, CA87 badań
- St. Louis, MO73 badań
- Chicago, IL61 badań
- Baltimore, MD60 badań
- San Antonio, TX59 badań
- Columbus, OH57 badań
- Washington, DC55 badań
Inne badania w mieście Pittsburgh
- Nowotwory (wszystkie typy)41 badań
- Rak piersi39 badań
- Rak jelita grubego i odbytnicy32 badań
- Nowotwór przerzutowy31 badań
- Czerniak31 badań
- Rak jajnika30 badań
- Rak endometrium23 badań
- Rak prostaty23 badań
- Rak płuc23 badań
- Rak płaskonabłonkowy głowy i szyi22 badań
- Udar22 badań
- Depresja22 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.